Corning Data and Estimate of Cell & Gene Therapy Clinical Market by Product (Consumables (Media, FBS), Equipment (Bioreactor, Centrifuge, Incubator, Microscope, Autoclave)), Application (Stem Cell, Vaccines, Therapeutic proteins), End User (Pharma, Research Institutes) - Global Forecast – 2021 to 2027.

ID: VPR/HC/163 Publishing Year: January 2021 Pages: 119 Format:   


Market Overview:

The Corning Data and Estimate of Cell & Gene Therapy Clinical Market was valued at $XXX billion in2019, and it is expected to reach $XXX billion by 2027, registering a CAGR of XX% from 2021 to 2027.The Cell and Gene therapy growth has been attributed to important factors in market such as rising prevalence of cancer and chronic disease, increasing number of clinical trials for cell and gene therapy, steady investment in the Cell And Gene Therapy Market and favorable monitoring environment. Cellular therapies are continuously gaining popularity in science industry. Increase in funding from private and government organizations, encourage development of cellular therapies act as drivers for the market. This market is experiencing major growth due to the rising demand for monoclonal antibodies, growth in funding for cell-based research, growing preference for single use technologies, rising awareness about the advantages of cell culture-based vaccines, and increasing focus on personalized medicine.
Increase in usage of Automating System In Cell & Gene Therapy Clinical applications is one of the major market drivers .Automated systems reduce manpower and cost required during the production of Cell Therapy Products, Gene therapies, and other biologics which is leading to robust and reliable processes.

Segment Overview:

 The Corning Data and Estimate of Cell & Gene Therapy Clinical Market is segmented by Product, Application and End User.

Product Insights:

The Product Insights is divided into equipment and consumables. The consumables segment is further divided into sera, media, & reagents. The sera, media, and reagents segment is anticipated to register for the major share of the markets. There are various cell culture applications such as biopharmaceutical production, vaccine production, toxicology, and drug discovery. Sera, media, and reagents are vital part of cell culture experiments and help in achieving better results.

Application Insights:

The application insights are segmented into Biopharmaceutical Production, Stem Cell Technology, Diagnostics, Drug Discovery & Development. The biopharmaceutical segment captures the largest revenue share as there is an increase in the approvals of biopharmaceutical products. The growing prevalence of cancer and funding for cancer research are major factors driving the growth of Stem Cell Technology In The Application Insights of the Market.

End User Insights:

The end user insight of the market is divided into pharmaceutical & biotechnology companies, research institutes, the cosmetics industry, and other end users. Pharmaceutical & biotechnology companies have accounted largest share of the market in the past years. Large number of pharmaceutical & biotechnology companies, increase in R&D spending in these companies, and the increase in preference for alternative testing models over animal techniques are the key drivers in this end-user segment.

The key segments are:

By Product:

  • Equipment
    • Bioreactors
    • Storage Equipment
    • Supporting Equipment
  • Consumables
    • Sera, Media, and Reagents

By Application:

  • Biopharmaceutical Production
    • Vaccine Production
    • Therapeutic Proteins
  • Stem Cell Technology
  • Diagnostics
  • Drug Discovery & Development
  • Tissue Engineering & Regenerative Medicine
  • Other Applications

By End User:

  • Pharmaceutical and Biotechnology Companies
  • Hospitals and Diagnostic Laboratories
  • Research Institutes
  • Cell Banks

By Region:

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • RoE
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia Pacific

TABLE OF CONTENTS:

CHAPTER 1 MARKET INTRODUCTION

1.1. REPORT OVERVIEW

1.2. SCOPE OF THE STUDY

1.3. PRIMARY MARKET SEGMENTS

1.4. RESEARCH METHODOLOGY

CHAPTER 2 EXECUTIVE SUMMARY

2.1. C-LEVEL EXECUTIVE’S OVERVIEW AND PERSPECTIVES

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE

3.2. PRINCIPAL FINDINGS

3.2.1. Key investment pockets

3.2.2. Leading winning strategies

  3.2.3 Key Player Positioning

3.3. PORTERS FIVE FORCES OF COMPETITIVE ANALYSIS

 3.4. MARKET DYNAMICS

3.4.1. Drivers

3.4.2. Restraints

3.4.3. Opportunities

3.4.4. Impact Analysis

3.5. IMPACT OF COVID-19 ON THIS MARKET

CHAPTER 4 Corning data and estimate of cell & gene therapy clinical market, BY Product

4.1. SYNOPSIS

4.1.1. Market size and forecast

4.2. Equipment

4.2.1. Key market trends

4.2.2. Growth factors and opportunities

4.2.3. Market size and forecast

4.3. Consumables

4.3.1. Key market trends

4.3.2. Growth factors and opportunities

4.3.3. Market size and forecast

CHAPTER 5 Corning data and estimate of cell & gene therapy clinical market, BY Application

5.1. SYNOPSIS

5.1.1. Market size and forecast

5.2. Biopharmaceutical Production

5.2.1. Key market trends

5.2.2. Growth factors and opportunities

5.2.3. Market size and forecast

5.3. Stem Cell Technology

5.3.1. Key market trends

5.3.2. Growth factors and opportunities

5.3.3. Market size and forecast

5.4. Diagnostics

5.4.1. Key market trends

5.4.2. Growth factors and opportunities

5.4.3. Market size and forecast

5.5. Drug Discovery & Development

5.5.1. Key market trends

5.5.2. Growth factors and opportunities

5.5.3. Market size and forecast

5.6. Tissue Engineering &Regenerative Medicine

5.6.1. Key market trends

5.6.2. Growth factors and opportunities

5.6.3. Market size and forecast

5.7. Other Application

5.7.1. Key market trends

5.7.2. Growth factors and opportunities

5.7.3. Market size and forecast

CHAPTER 6 Corning data and estimate of cell & gene therapy clinical market, BY End user

6.1. SYNOPSIS

6.1.1. Market size and forecast

6.2. Pharmaceutical Companies

6.2.1. Key market trends

6.2.2. Growth factors and opportunities

6.2.3. Market size and forecast

6.3. Hospitals and Diagnostics Laboratories

6.3.1. Key market trends

6.3.2. Growth factors and opportunities

6.3.3. Market size and forecast

6.4. Research Institutes

6.4.1. Key market trends

6.4.2. Growth factors and opportunities

6.4.3. Market size and forecast

6.5. Cell Banks

6.5.1. Key market trends

6.5.2. Growth factors and opportunities

6.5.3. Market size and forecast

CHAPTER 7 Corning data and estimate of cell & gene therapy clinical market, BY REGION

7.1 SYNOPSIS

  7.1.1. Market size and forecast

7.2 North America

7.2.1 Key market trends

7.2.2 Competitive scenario

7.2.3 Key growth factors and opportunities

7.2.4 Market size and forecast

7.3 Europe

7.3.1 Key market trends

7.3.2 Competitive scenario

7.3.3 Key growth factors and opportunities

7.3.4 Market size and forecast

7.4 Asia Pacific

7.4.1 Key market trends

7.4.2 Competitive scenario

7.4.3 Key growth factors and opportunities

7.4.4 Market size and forecast

7.5 LAMEA

7.5.1 Key market trends

7.5.2 Key growth factors and opportunities

7.5.3 Market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. Thermo Fisher Scientific(US)

8.1.1. Company overview

8.2.2. Company snapshot

8.1.3. Product portfolio

8.1.4. Business performance

8.1.5. Key strategic moves and developments

8.2 Merck KGaA (Germany)

8.2.1. Company overview

8.2.2. Company snapshot

8.2.3. Operating business segments

8.2.4. Product portfolio

8.2.5. Business performance

8.2.6. Key strategic moves and developments

8.3. GE Healthcare (US)

8.3.1. Company overview

8.3.2. Company snapshot

8.3.3. Operating business segments

8.3.4. Product portfolio

8.3.5. Business performance

8.3.6. Key strategic moves and developments

8.4. Lonza (Switzerland)

8.4.1. Company overview

8.4.2. Company snapshot

8.4.3. Operating business segments

8.4.4. Product portfolio

8.4.5. Business performance

8.4.6. Key strategic moves and developments

8.5. Becton, Dickinson and company (US)

8.5.1. Company overview

8.5.2. Company snapshot

8.5.3. Operating business segments

8.5.4. Product portfolio

8.5.5. Business performance

8.5.6. Key strategic moves and developments

8.6. Corning Incorporated (US)

8.6.1. Company overview

8.6.2. Company Snapshot

8.6.3. Operating business segments

8.6.4. Product portfolio

8.6.5. Business performance

8.6.6. Key strategic moves and developments

8.7. Eppendorf AG (Germany)

8.7.1. Company overview

8.7.2. Company snapshot

8.7.3. Operating business segments

8.7.4. Product portfolio

8.7.5. Business performance

8.7.6. Key strategic moves and developments

8.8. HI Media Laboratories (India)

8.8.1. Company overview

8.8.2. Company snapshot

8.8.3. Operating business segments

8.8.4. Product portfolio

8.8.5. Business performance

8.8.6. Key strategic moves and developments

8.9. Sartorius AG (Germany)

8.9.1. Company overview

8.9.2. Company snapshot

8.9.3. Operating business segments

8.9.4. Product portfolio

8.9.5. Business performance

8.9.6. Key strategic moves and developments

8.10. PromoCell GmBh (Germany)

8.10.1. Company overview

8.10.2. Company snapshot

8.10.3. Operating business segments

8.10.4. Product portfolio

8.10.5. Business performance

8.10.6. Key strategic moves and developments

8.11. Danaher Corporations (US)

8.11.1. Company overview

8.11.2. Company snapshot

8.11.3. Operating business segments

8.11.4. Product portfolio

8.11.5. Business performance

8.11.6. Key strategic moves and developments

8.12. Irvine Scientific (US)

8.12.1. Company overview

8.12.2. Company snapshot

8.12.3. Operating business segments

8.12.4. Product portfolio

8.12.5. Business performance

8.12.6. Key strategic moves and developments

8.13. Invivo Gen (US)

8.13.1. Company overview

8.13.2. Company snapshot

8.13.3. Operating business segments

8.13.4. Product portfolio

8.13.5. Business performance

8.13.6. Key strategic moves and developments

8.14. CellGenix Gmbh (Germany)

8.14.1. Company overview

8.14.2. Company snapshot

8.14.3. Operating business segments

8.14.4. Product portfolio

8.14.5. Business performance

8.14.6. Key strategic moves and developments


PURCHASE OPTIONS




    ADD TO CART

CONTACT US
CALL US ON
( +91-935-919-4956 )

CONTACT EMAIL
[email protected]
PURCHASE OPTIONS




    ADD TO CART

CONTACT US
CALL US ON
( +91-935-919-4956 )

CONTACT EMAIL
[email protected]